249 related articles for article (PubMed ID: 24793304)
21. The novel reversible fatty acid amide hydrolase inhibitor ST4070 increases endocannabinoid brain levels and counteracts neuropathic pain in different animal models.
Caprioli A; Coccurello R; Rapino C; Di Serio S; Di Tommaso M; Vertechy M; Vacca V; Battista N; Pavone F; Maccarrone M; Borsini F
J Pharmacol Exp Ther; 2012 Jul; 342(1):188-95. PubMed ID: 22514334
[TBL] [Abstract][Full Text] [Related]
22. Drug therapy of neuropathic pain: current developments and future perspectives.
Muthuraman A; Singh N; Jaggi AS; Ramesh M
Curr Drug Targets; 2014 Feb; 15(2):210-53. PubMed ID: 24093749
[TBL] [Abstract][Full Text] [Related]
23. The multiplicity of spinal AA-5-HT anti-nociceptive action in a rat model of neuropathic pain.
Malek N; Kostrzewa M; Makuch W; Pajak A; Kucharczyk M; Piscitelli F; Przewlocka B; Di Marzo V; Starowicz K
Pharmacol Res; 2016 Sep; 111():251-263. PubMed ID: 27326920
[TBL] [Abstract][Full Text] [Related]
24. Targeting Members of the Chemokine Family as a Novel Approach to Treating Neuropathic Pain.
Pawlik K; Mika J
Molecules; 2023 Jul; 28(15):. PubMed ID: 37570736
[TBL] [Abstract][Full Text] [Related]
25. Recent trends in neuropathic pain patents.
Maia RD
Expert Opin Ther Pat; 2017 May; 27(5):539-546. PubMed ID: 27998196
[TBL] [Abstract][Full Text] [Related]
26. Receptor and Molecular Targets for the Development of Novel Opioid and Non-Opioid Analgesic Therapies.
Chen R; Coppes OJM; Urman RD
Pain Physician; 2021 Mar; 24(2):153-163. PubMed ID: 33740349
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms and treatment of neuropathic pain.
Vranken JH
Cent Nerv Syst Agents Med Chem; 2009 Mar; 9(1):71-8. PubMed ID: 20021340
[TBL] [Abstract][Full Text] [Related]
28. Challenges in translational drug research in neuropathic and inflammatory pain: the prerequisites for a new paradigm.
Taneja A; Della Pasqua O; Danhof M
Eur J Clin Pharmacol; 2017 Oct; 73(10):1219-1236. PubMed ID: 28894907
[TBL] [Abstract][Full Text] [Related]
29. Gabapentin for chronic neuropathic pain and fibromyalgia in adults.
Moore RA; Wiffen PJ; Derry S; Toelle T; Rice AS
Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD007938. PubMed ID: 24771480
[TBL] [Abstract][Full Text] [Related]
30. Novel sodium channel antagonists in the treatment of neuropathic pain.
Rivara M; Zuliani V
Expert Opin Investig Drugs; 2016; 25(2):215-26. PubMed ID: 26576738
[TBL] [Abstract][Full Text] [Related]
31. Emerging therapies for neuropathic pain: new molecules or new indications for old treatments?
Bouhassira D; Attal N
Pain; 2018 Mar; 159(3):576-582. PubMed ID: 29447137
[TBL] [Abstract][Full Text] [Related]
32. Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain.
Leung A; Wallace MS; Ridgeway B; Yaksh T
Pain; 2001 Mar; 91(1-2):177-87. PubMed ID: 11240090
[TBL] [Abstract][Full Text] [Related]
33. Chronic neuropathic pain: mechanisms, drug targets and measurement.
Finnerup NB; Sindrup SH; Jensen TS
Fundam Clin Pharmacol; 2007 Apr; 21(2):129-36. PubMed ID: 17391285
[TBL] [Abstract][Full Text] [Related]
34. Effects of ralfinamide in models of nerve injury and chemotherapy-induced neuropathic pain.
Liang X; Yu G; Su R
Eur J Pharmacol; 2018 Mar; 823():27-34. PubMed ID: 29408090
[TBL] [Abstract][Full Text] [Related]
35. Antinociceptive activity of α4β2* neuronal nicotinic receptor agonist A-366833 in experimental models of neuropathic and inflammatory pain.
Nirogi R; Jabaris SL; Jayarajan P; Abraham R; Shanmuganathan D; Rasheed MA; Royapalley PK; Goura V
Eur J Pharmacol; 2011 Oct; 668(1-2):155-62. PubMed ID: 21756895
[TBL] [Abstract][Full Text] [Related]
36. Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro.
Slivicki RA; Xu Z; Mali SS; Hohmann AG
Pharmacol Res; 2019 Apr; 142():267-282. PubMed ID: 30739035
[TBL] [Abstract][Full Text] [Related]
37. Targeting angiotensin II type 2 receptor pathways to treat neuropathic pain and inflammatory pain.
Smith MT; Muralidharan A
Expert Opin Ther Targets; 2015 Jan; 19(1):25-35. PubMed ID: 25315162
[TBL] [Abstract][Full Text] [Related]
38. Neuropathic pain: models and mechanisms.
Jarvis MF; Boyce-Rustay JM
Curr Pharm Des; 2009; 15(15):1711-6. PubMed ID: 19442185
[TBL] [Abstract][Full Text] [Related]
39. Pharmacologic management part 1: better-studied neuropathic pain diseases.
Backonja MM; Serra J
Pain Med; 2004 Mar; 5 Suppl 1():S28-47. PubMed ID: 14996228
[TBL] [Abstract][Full Text] [Related]
40. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.
Davis MP
Expert Opin Investig Drugs; 2014 Aug; 23(8):1123-40. PubMed ID: 24836296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
